Phase I/II study of low-dose azacytidine in patients with chronic myeloid leukemia who have minimal residual disease while receiving therapy with tyrosine kinase inhibitors

Abhishek Maiti, Jorge E. Cortes, Yolanda D. Brown, Hagop M. Kantarjian

Research output: Contribution to journal › Letter › peer-review

5 Scopus citations

Fingerprint

Dive into the research topics of 'Phase I/II study of low-dose azacytidine in patients with chronic myeloid leukemia who have minimal residual disease while receiving therapy with tyrosine kinase inhibitors'. Together they form a unique fingerprint.